New treatment strategies for targeted therapy of breast cancer

HUANG Jing-bin; ZHONG Yan-qiang

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 29 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2011 > 29(5): 324-327

HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.

Citation:

HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.

New treatment strategies for targeted therapy of breast cancer

Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2010-12-30
Rev Recd Date: 2011-03-17

Abstract

Common therapies of breast cancer such as chemotherapy, radiotherapy had severe systemic side effects. To reduce those side effects, developing strategies of targeted therapy was necessary. Three research fields on targeted therapy of breast cancer were reviewed in this paper: antibody based breast cancer therapy, microcarrier mediated breast cancer therapy, breast cancer stem cell targeted therapy. The ideas of the tree strategies had been illustrated and the challenges existing in the strategies also been analyzed. Some opinions had been put forward to solve this challenges.
- breast cancer,
- breast cancer stem cell,
- microcarrier,
- targeted therapy

References

[1]	Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives[J]. Endocr Relat Cancer, 2009, 16 (3): 675.
[2]	Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR-2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells[J]. Mol Cancer Res, 2008, 6 (10): 1630.
[3]	Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2[J]. Cell Cycle, 2008, 7 (23): 3747.
[4]	Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances[J]. Oncologist, 2005, 10 (6): 382.
[5]	Cesare G, PaoloM, Antonio R, et al. The role of bevacizumab in the treatment of non-small cell lung cancer: current Indications and future developments[J]. The Oncologist, 2007, 12 (10) : 1183.
[6]	Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for matastatic breast cancer[J]. N Engl J Med, 2007, 357 (26): 2666.
[7]	Park JW,Neve RM, Szollosi J,et al. Unraveling the biologic and clinical comp lexities of HER2[J]. Clin Breast Cancer, 2008, 8 (5) : 392.
[8]	Freudenberg JA,Wang Q, Katsumata M, et al. The role of HER2 in early breast cancermetastasis and the origins of resistance to HER2-targeted therapies[J]. Exp Mol Pathol, 2009, 87 (1) : 1.
[9]	SpectorNL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer[J]. J Clin Oncol, 2009, 27 (34) : 5838.
[10]	Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies[J]. Lancet Oncol, 2009, 10 (12) : 1179.
[11]	Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients ( pts) with HER2-positive metastatic breast cancer (MBC) [J]. J ClinOncol, 2008, 26 (5) : 1027.
[12]	Mulik RS, Mnkknen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis[J]. Int J Pharm, 2010, 398 (1-2): 190.
[13]	Zheng Y, Yu B, Weecharangsan W,et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells[J]. Int J Pharm, 2010, 390 (2): 234.
[14]	Acharya S,Dilnawaz F, Sahoo SK, et al. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy[J]. Biomaterials, 2009, 30 (29): 5737.
[15]	Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J]. Biomaterials, 2010, 31 (8): 2278.
[16]	Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138 (4): 645.
[17]	Riccioni R, Dupuis ML, Bernabei M, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor[J]. Blood Cells Mol Dis, 2010, 45 (1): 86.
[18]	Fuchs D, Heinold A, Opelz G, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells[J]. Biochem Biophys Res Commun, 2009 , 390 (3): 743.
[19]	Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancercells to chemotherapy[J]. J Natl Cancer Inst, 2008, 100 (9): 672.
[20]	Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112: 533.
[21]	Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes[J] J Control Release, 2008, 129 (1): 18.
[22]	Zhou J, Zhang H, Gu P, et al. NF-kB pathway inhibitors preferentially inhibit breast cancer stem-like cells[J]. Breast Cancer Res Treat, 2008, 111 (3): 419.
[23]	Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission[J]. Cancer Res, 2009, 69 (19): 7507.
[24]	Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo[J]. Cell Cycle, 2010, 9 (1): 188.
[25]	Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells[J]. Cell Cycle, 2009, 8(13): 2031.
[26]	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100 (7): 3983.
[27]	Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44⁺/CD24^- and CD133⁺ cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10 (1): R10.
[28]	Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers[J]. PLoS One, 2009, 4 (12): e8377.
[29]	Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1 (5): 555.
[30]	Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content[J]. Cell, 2010, 40 (1): 62.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3183) PDF downloads(549) Cited by()

Proportional views

New treatment strategies for targeted therapy of breast cancer

Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2010-12-30

Rev Recd Date: 2011-03-17

Key words:

Abstract: Common therapies of breast cancer such as chemotherapy, radiotherapy had severe systemic side effects. To reduce those side effects, developing strategies of targeted therapy was necessary. Three research fields on targeted therapy of breast cancer were reviewed in this paper: antibody based breast cancer therapy, microcarrier mediated breast cancer therapy, breast cancer stem cell targeted therapy. The ideas of the tree strategies had been illustrated and the challenges existing in the strategies also been analyzed. Some opinions had been put forward to solve this challenges.

HTML

Reference (30)

[1]	Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives[J]. Endocr Relat Cancer, 2009, 16 (3): 675.
[2]	Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR-2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells[J]. Mol Cancer Res, 2008, 6 (10): 1630.
[3]	Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2[J]. Cell Cycle, 2008, 7 (23): 3747.
[4]	Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances[J]. Oncologist, 2005, 10 (6): 382.
[5]	Cesare G, PaoloM, Antonio R, et al. The role of bevacizumab in the treatment of non-small cell lung cancer: current Indications and future developments[J]. The Oncologist, 2007, 12 (10) : 1183.
[6]	Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for matastatic breast cancer[J]. N Engl J Med, 2007, 357 (26): 2666.
[7]	Park JW,Neve RM, Szollosi J,et al. Unraveling the biologic and clinical comp lexities of HER2[J]. Clin Breast Cancer, 2008, 8 (5) : 392.
[8]	Freudenberg JA,Wang Q, Katsumata M, et al. The role of HER2 in early breast cancermetastasis and the origins of resistance to HER2-targeted therapies[J]. Exp Mol Pathol, 2009, 87 (1) : 1.
[9]	SpectorNL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer[J]. J Clin Oncol, 2009, 27 (34) : 5838.
[10]	Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies[J]. Lancet Oncol, 2009, 10 (12) : 1179.
[11]	Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients ( pts) with HER2-positive metastatic breast cancer (MBC) [J]. J ClinOncol, 2008, 26 (5) : 1027.
[12]	Mulik RS, Mnkknen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis[J]. Int J Pharm, 2010, 398 (1-2): 190.
[13]	Zheng Y, Yu B, Weecharangsan W,et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells[J]. Int J Pharm, 2010, 390 (2): 234.
[14]	Acharya S,Dilnawaz F, Sahoo SK, et al. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy[J]. Biomaterials, 2009, 30 (29): 5737.
[15]	Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J]. Biomaterials, 2010, 31 (8): 2278.
[16]	Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138 (4): 645.
[17]	Riccioni R, Dupuis ML, Bernabei M, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor[J]. Blood Cells Mol Dis, 2010, 45 (1): 86.
[18]	Fuchs D, Heinold A, Opelz G, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells[J]. Biochem Biophys Res Commun, 2009 , 390 (3): 743.
[19]	Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancercells to chemotherapy[J]. J Natl Cancer Inst, 2008, 100 (9): 672.
[20]	Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112: 533.
[21]	Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes[J] J Control Release, 2008, 129 (1): 18.
[22]	Zhou J, Zhang H, Gu P, et al. NF-kB pathway inhibitors preferentially inhibit breast cancer stem-like cells[J]. Breast Cancer Res Treat, 2008, 111 (3): 419.
[23]	Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission[J]. Cancer Res, 2009, 69 (19): 7507.
[24]	Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo[J]. Cell Cycle, 2010, 9 (1): 188.
[25]	Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells[J]. Cell Cycle, 2009, 8(13): 2031.
[26]	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100 (7): 3983.
[27]	Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44⁺/CD24^- and CD133⁺ cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10 (1): R10.
[28]	Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers[J]. PLoS One, 2009, 4 (12): e8377.
[29]	Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1 (5): 555.
[30]	Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content[J]. Cell, 2010, 40 (1): 62.

Message Board

New treatment strategies for targeted therapy of breast cancer

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views